Johnson & Johnson JNJ

$259.48 +4.70 (1.84%)

Valuation

Market cap
609,535,488,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.58
Forward PE
22.19
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
2,689,481
Avg volume
6,716,070
Day's range
$255.73 – $260.68
Shares out
2,409,898,000
Stochastic %K
15%
Beta
0.21
Analysts
Strong Sell
Price target
$282.48

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Pope_of_Profit Oct 7, 4:09 PM
$JNJ correction probably over, I don't like to swing into ERs but might make an exception here
0 replies
Gebinator Oct 7, 3:17 PM
$SLS $JNJ $MRK $ABBV It's worth noting today $ABBV reached an all-time high on news of breakthrough therapy designations for its ADC drug candidates. With an MC verging on a half-trillion dollars, I would accept a stock-swap of some sort with $ABBV for the whole $SLS enchilada. Of course, the same goes for $JNJ, $MRK or any dark horse such as $LLY. Regardless of who and exact circumstances -- my final BO expectation remains ~ $40 Billy 🦖 MINIMUM
1 replies
E458 Oct 7, 2:13 PM
$SPY looks like $JNJ struggling with 260 and we may lose healthcare greenies soon
0 replies
SparkyReturns Oct 7, 1:55 PM
$ICU A new BDD just for SEPSIS! 7 BDDs?!? Same device?! And a clean one, just for SEPSIS! The current adult study will have enough data on sepsis that this could sail through quickly. This is INSANELY undervalued. This will actually help big pharma save patients so they can then go on other medicines and treatments to address underlying conditions. Congratulations Seastar! (ICU) $JNJ $BDX $MDT $MRNA
1 replies
E458 Oct 7, 1:48 PM
$SPY as usual MM hedging with $JNJ and trying their best with $AAPL
0 replies
holdinglongerandstronger Oct 6, 9:17 PM
$SLS $JNJ $AZN $JNJ $AZN appreciate this VERY interesting/helpful find each investor should take time to read/digest ....MAKE NO MISTAKE - NEWS IMMINENT WE ARE ON TRACK AND ON RADAR REMAIN FOCUSED 💪🏾🔥😉
0 replies
dewmoore Oct 6, 8:09 PM
$SLS Not me realizing that November 11 earnings date is literally the ultimate deadline for them to spill the tea. If we're sitting at 79 and playing the quiet period game, they legally can't hide it past the Q3 report. They did the exact same thing back in May, so whether flu season pushes that final event over the edge or management has to drop the numbers live on the call, the silence is breaking in about a month. We love a scheduled catalyst bestie. LOL #justsaying. $SLS PS -- I keep praying $JNJ or $LLY or $MRK just starts the bidding war at $30B aka $148 to $158 per share WOW what an amazing morning that would be!!!! GLTA see ya soon in the words of the CEO no more posts until I see 80 or wait 79 in november
0 replies
SellasgpsCurativeBAT11 Oct 6, 6:49 PM
$SLS $JNJ $AZN Bob, When you see $JNJ and $AZN openly touting GPS as a Breakthrough and then one deleting his Linkedln post because he just spilled the magic beans. All Longs here knew this was the final Outcome. ✌️🙏❤️‍🩹
1 replies